Navigation Links
Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study

o work by targeting the tumor and its vasculature.

Integrins are cell surface receptors that are improperly regulated in many cancer types which enables them to enhance tumor growth, survival and invasiveness. Integrins are fundamental in the process of angiogenesis (blood vessel growth) – a process that is essential for tumors as it enables them to grow past a finite size.

In addition to the Merck KGaA-initiated studies, the U.S. National Cancer Institute (NCI) is sponsoring a number of clinical trials under a Cooperative Research and Development Agreement (CRADA) with Merck KGaA for the development of cilengitide. An initial Phase I/II study in adult high-grade glioma (including glioblastoma) patients showed encouraging results.(5) Seven NCI-sponsored studies with cilengitide monotherapy in various tumor types, including newly diagnosed glioblastoma, recurrent glioblastoma in adults and recurrent brain tumors in children are currently ongoing. An additional NCI sponsored Phase II trial combining cilengitide with radiotherapy and temozolomide in patients newly diagnosed with glioblastoma is also ongoing.

Merck KGaA has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas, such as the use of Erbitux in colorectal cancer, squamous cell carcinoma of the head and neck and non-small cell lung cancer. Merck KGaA, Darmstadt, Germany, licensed the right to market Erbitux outside the US and Canada from ImClone Systems Incorporated of New York in 1998. In Japan, Merck KGaA has co-exclusive marketing rights with ImClone Systems. Merck KGaA has also acquired the rights for the cancer treatment UFT® (tegafur-uracil) – an oral chemotherapy administered with folinic acid (FA) for the first-line treatment of metastatic colorectal cancer.

Merck KGaA is also investigating among other cancer treatments the use of Stimuvax® (formerly referred to as BLP25 Li
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
11. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

Post Your Comments:
(Date:11/26/2009)...a, Nov. 26 The 2009 Frost & Su...he Generic Pharmaceutical Market is presented to C...tp://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ...lowing criteria were used to benchmark Cipla Medpr...rategy and implementation, degree of innovation in...
(Date:11/25/2009)...RNewswire-FirstCall/ -- Hologic, Inc. (Hologic or ..., manufacturer and supplier of premium diagnostics...dicated to serving the healthcare needs of women, ...ciety of North America (RSNA) at McCormick Place i... highlight our new SecurView(®) DX multimodal...
(Date:11/25/2009)...ire/ -- BioTrends Research Group, Inc. released Wa...rt, the first in a multi-phase syndicated market r...tho-Biotech,s Stelara, from product launch through...of the report provides quantitative information fr...ation from a subset of 20. The reports assess tri...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 4590 1UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 4590 2UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 4590 3TransUnion Revenue Manager 28SM 29 Meets Healthcare Challenges Brought On By Todays Economy with New Features 48846 1TransUnion Revenue Manager 28SM 29 Meets Healthcare Challenges Brought On By Todays Economy with New Features 48846 2TransUnion Revenue Manager 28SM 29 Meets Healthcare Challenges Brought On By Todays Economy with New Features 48846 3OpenQ is Awarded Prestigious Life Sciences Industry Award 12610 1OpenQ is Awarded Prestigious Life Sciences Industry Award 12610 2
(Date:11/27/2009)... NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswire/ -...ssional cycling team dedicated to ethical sporting...mpions, announced today that it will become Team G... Optical as a new sponsor of the team. Transitions...aptive eyewear, offering the most advanced photoch...
(Date:11/27/2009)... XenaCare Holdings has announced that ...Foundation, one of the largest nonprofit organizat...alth education. , Delray ...ldings, Inc. (OTCBB: XCHO), a company specializing...mer healthcare products, has announced today that ...
(Date:11/27/2009)... to bring unprecedented medical, economic burdens,...lthDay News) -- The number of people with diabetes...he next 25 years, a new study predicts. , That ...n people with the disease, up from 23.7 million to...people with diabetes will triple, the study also w...
(Date:11/27/2009)... Voyant Health™ announced today ...licensed its TraumaCad Enterprise orthopedic templ...olution. , (PRWEB) Novemb...y that Spectrum Health (Grand Rapids, Michigan) ha...plating solution and its TraumaCad Extend workflow...
(Date:11/27/2009)... Specialist manufacturers who use medi...saving millions of dollars by bringing in technolo...creasing numbers of pro-active medical manufacture... concept stage of their projects, ensuring that pr...processes or potentially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...anks were found to be deficient in nutrients or ca...h of the deprived in the province, researchers fro...ilable in Canadian Journal of Public Health, exami... meant to last three days, contained calories suff...
... so, is how researcher Dr. Jane Carlton of the New...e the bacterium Trichomonas.// The one-cell...iasis, a severe itchy genital infection, which is ...ddition to causing uncomfortable itching in the ge...
...gh medicine to toddlers, parents need to be cautio...to benefit them. // The Centre for Disease Cont...gainst giving over the counter (OTC) drugs to thei...roup of six months in 2005 revealed that they had ...
...he use of viruses like that of the common cold t... Leonard Seymour, a professor of gene therapy at O...ing cancer cells with viruses. While the techni...ich have broken away for the tumor, entered the bl...
...t a cup of coffee after exercise can reduce sorene... for people new to gym work out, since they tend t...use caffeine to reduce the pain, it may make it ea... Victor Maridakis and his colleagues observed nin...
... for a live chat with Indian American astronaut Su...er as she spoke from her zero-gravity// home among...loating loosely, a scientific fact they had only r...stronaut Michael Lopez-Algeria, both in the Intern...
Other Medicine News:Health News:Humble Cold to Combat Cancer 2Health News:Indian Students Thrilled to Talk to Sunita Williams 2
...boratory," it brings to mind images of test tubes,...tems. With the introduction of the Brady Code Read... list of critical lab tools. Brady Corporation has...he lab with the introduction of the CR2. It is the...
VisionMate1
Laboratory Table; Sealed Laminate Top
Tables
Medicine Products: